In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Emergent Biosolutions Inc (NYSE: EBS) closed at $7.63 down -2.55% from its previous closing price of $7.83. In other words, the price has decreased by -$2.55 from its previous closing price. On the day, 0.84 million shares were traded. EBS stock price reached its highest trading level at $7.87 during the session, while it also had its lowest trading level at $7.53.
Ratios:
For a deeper understanding of Emergent Biosolutions Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.63. For the most recent quarter (mrq), Quick Ratio is recorded 3.00 and its Current Ratio is at 5.66. In the meantime, Its Debt-to-Equity ratio is 1.26 whereas as Long-Term Debt/Eq ratio is at 1.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
The Benchmark Company Upgraded its Hold to Buy on March 07, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 15 ’25 when Zoon Kathryn C sold 7,086 shares for $8.87 per share. The transaction valued at 62,853 led to the insider holds 71,799 shares of the business.
KATHRYN ZOON bought 7,086 shares of EBS for $62,853 on Aug 15 ’25. On Aug 12 ’25, another insider, DeGolyer Donald W, who serves as the Director of the company, sold 7,844 shares for $8.65 each. As a result, the insider received 67,831 and left with 137,659 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 417739456 and an Enterprise Value of 815868864. As of this moment, Emergent’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.11, and their Forward P/E ratio for the next fiscal year is 7.44. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.48 while its Price-to-Book (P/B) ratio in mrq is 0.76. Its current Enterprise Value per Revenue stands at 0.958 whereas that against EBITDA is 3.763.
Stock Price History:
The Beta on a monthly basis for EBS is 2.05, which has changed by 0.014627695 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, EBS has reached a high of $12.73, while it has fallen to a 52-week low of $4.02. The 50-Day Moving Average of the stock is 1.33%, while the 200-Day Moving Average is calculated to be 2.61%.
Shares Statistics:
For the past three months, EBS has traded an average of 1.29M shares per day and 1035450 over the past ten days. A total of 53.70M shares are outstanding, with a floating share count of 51.05M. Insiders hold about 4.31% of the company’s shares, while institutions hold 74.47% stake in the company. Shares short for EBS as of 1755216000 were 9815705 with a Short Ratio of 7.61, compared to 1752537600 on 9056841. Therefore, it implies a Short% of Shares Outstanding of 9815705 and a Short% of Float of 18.59.
Earnings Estimates
The stock of Emergent Biosolutions Inc (EBS) is currently being evaluated by 1.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.21, with high estimates of $0.21 and low estimates of $0.21.
Analysts are recommending an EPS of between $1.19 and $1.19 for the fiscal current year, implying an average EPS of $1.19. EPS for the following year is -$1.9, with 1.0 analysts recommending between -$1.9 and -$1.9.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $203.67M this quarter.It ranges from a high estimate of $213M to a low estimate of $198M. As of the current estimate, Emergent Biosolutions Inc’s year-ago sales were $293.8MFor the next quarter, 3 analysts are estimating revenue of $233.67M. There is a high estimate of $251M for the next quarter, whereas the lowest estimate is $220M.
A total of 3 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $828.28M, while the lowest revenue estimate was $783.1M, resulting in an average revenue estimate of $800.83M. In the same quarter a year ago, actual revenue was $1.04BBased on 2 analysts’ estimates, the company’s revenue will be $918.74M in the next fiscal year. The high estimate is $1.16B and the low estimate is $682.47M.
